CD532 |
| Catalog No.GC48982 |
CD532는 IC50이 45nM인 강력한 Aurora A 키나제 억제제입니다. CD532는 Aurora A 키나제 활성을 차단하고 MYCN의 분해를 유도하는 이중 효과가 있습니다. CD532는 또한 AURKA와 직접 상호 작용할 수 있으며 전체적인 형태 변화를 유도합니다. CD532는 암 연구에 사용될 수 있습니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1639009-81-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
CD532 is an inhibitor of Aurora A kinase activity (IC50 = 48 nM) and the protein-protein interaction between N-Myc and Aurora A kinase.1 It also inhibits several cyclin-dependent kinases (CDKs), FGFRs, MEKs, and PDGFRs, as well as FLT3, KIT, and RET at 10 µM.2 CD532 induces degradation of N-Myc in SK-N-BE(2) neuroblastoma cells (EC50 = 223 nM).1 It prevents S-phase entry in SK-N-BE(2) cells when used at a concentration of 1 µM.1 CD532 (25 mg/kg) reduces tumor growth and increases survival in a MYCN-amplified SMS-KCN neuroblastoma mouse xenograft model.
1.Gustafson, W.C., Meyerowitz, J.G., Nekritz, E.A., et al.Drugging MYCN through an allosteric transition in Aurora kinase ACancer Cell26(3)414-427(2014) 2.Lee, J.K., Phillips, J.W., Smith, B.A., et al.N-Myc drives neuroendocrine prostate cancer initiated from human prostate epithelial cellsCancer Cell29(4)536-547(2016)
Average Rating: 5 (Based on Reviews and 35 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *